App aims to outsmart heart disease: digital coach tested in 790 patients
NCT ID NCT07332468
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a smartphone app that helps manage blood pressure, cholesterol, and blood sugar can lower heart disease risk better than standard care. About 790 adults at high risk for heart disease will use the app for one year, with doctors reviewing its suggestions. The goal is to see if digital coaching leads to better long-term heart health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- smartphone-based digital remote management platform
- What this could lead to
- If successful, this could show that a smartphone app helps people better manage heart disease risk factors like blood pressure and cholesterol.
- What could go wrong
- This is an early-stage trial with 790 participants, and the app's suggestions still need doctor approval, so results may not apply broadly or show clear benefit over usual care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Anzhen Hospital, Capital Medical University, Beijing, China
Beijing, China
-
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Shanghai, China
-
The First Affiliated Hospital of Dalian Medical University, Dalian, China
Dalian, China
-
The First Hospital of Jilin University, Changchun, China
Changchun, China
-
The Second Affiliated Hospital of Nanchang University, Nanchang, China
Nanchang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.